This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Written by Willy Frick with edits by Ken Grauer A woman in her 70s with a history of hypertension presented with acute onset shortness of breath. She was out walking her dog when she developed sudden dizziness and light-headedness. When EMS found her, she was dyspneic and diaphoretic. Her ECG is shown below: What do you think? The conventional machine algorithm interpreted this ECG as STEMI.
With Medicare now covering semaglutide for people with obesity and cardiovascular disease who don't have diabetes, a study looks at who that might include, depending on what cutoffs prescription plans apply.
A new observational study suggests the position in which responders initially place the two defibrillator pads on the body may make a significant difference in returning spontaneous blood circulation after shock from a defibrillator.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
(MedPage Today) -- The TESLA trial was unable to support a benefit to thrombectomy for stroke patients with large-core infarcts identified on noncontrast CT within 24 hours. Unlike other studies, endovascular therapy in TESLA conferred no significantly.
Extract from a Holter ECG, 2 continuous strips, recorded at 25 mm/s. At the top you can see a broad complex tachycardia without recognizable P waves, which ends spontaneously after 2 beats in the lower section. This is a VT. The very first beat in the 1st strip is most probably a fusion beat. After the end of the VT in the 2nd strip, a narrow QRS complex appears, here you can also recognize that atrial fibrillation is present.
The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.
80
80
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
The FDA decision to accept the new drug application for delgocitinib cream is also occurring alongside the drug’s acceptance by the European Commission.
Unfortunately, I can't remember who the author of this ECG is. Perhaps he/she will get in touch with me. However, the ECG is very nice (despite the less than optimal recording quality) and that's why I want to post it. I don't know the history. In the first section of the ECG we see coarse fibrillation waves and QRS complexes with very different RR intervals, which is why this is atrial fibrillation.
Familial hypercholesterolemia (FH), characterized by lifelong elevations in low-density lipoprotein cholesterol (LDL-C), is the most common autosomal-dominant genetic disorder in the world. Without treatment, individuals with FH, compared with those without FH, are at 10- to 20-times higher risk of early coronary artery disease and subsequent premature death.
A study based on clinical trial data found higher risks of stroke, heart attack, and hospital admission for heart failure in older cancer survivors. In the analysis published in the journal Cancer, chemotherapy was also linked to elevated rates of these conditions.
Nature Reviews Cardiology, Published online: 24 September 2024; doi:10.1038/s41569-024-01090-2 The 20th anniversary of Nature Reviews Cardiology comes at a time of exciting innovation for cardiovascular research and clinical cardiology, with the advent of nucleic acid-targeted therapeutics, applications of artificial intelligence, promotion of a healthy cardiovascular exposome, personalization of medicine, and recognition of the importance of diversity, equity and inclusion in health care.
* Caution : Language -Harsh. Likelihood of truth : High The flamboyant genius of Andreas Roland Gruntzig, from Zurich gifted us the path-breaking treatment modality for coronary stenosis five decades ago. After a series of experiments in animals and peripheral vessels, he proved with a single patient N-1 study that effectively treated refractory LAD angina in a 38-year-old man in 1977.
Atrial fibrillation (AF) is the most common arrhythmia worldwide, with increasing prevalence resulting from improved awareness, increased life expectancy, and advances in detection technology. Simultaneously, thanks to the revolutionary work of cardiac electrophysiology (EP) physicians, scientists, and industry, ablative treatment of complex arrhythmias including AF has achieved ever-increasing efficacy and safety.
Subgroup analyses revealed FMT delivered through endoscopy, nasojejunal tube, and rectal enema had a greater impact on clinical response, symptom improvement, and quality of life.
Nature Reviews Cardiology, Published online: 24 September 2024; doi:10.1038/s41569-024-01085-z Elsa Lawrence and Catherine Wilson discuss the study that reported the existence of a transient regenerative window in mammals.
Panelists discuss how familial chylomicronemia syndrome (FCS) imposes a significant economic burden on patients, affecting their ability to stay employed and manage the costs associated with long-term care and treatment.
External electric cardioversion (ECV) effectively converts atrial and ventricular arrhythmias and is also recommended for patients with cardiovascular implantable electronic devices (CIED) (1, 2). Some studies and case reports have demonstrated shock-related pacemaker events resulting in battery depletion, threshold rise, and increased risk of re-interventions (3, 4).
Panelists discuss how familial chylomicronemia syndrome (FCS) is characterized by severe hypertriglyceridemia and genetic mutations in the LPL gene, highlighting the key diagnostic criteria and complications, such as acute pancreatitis, while emphasizing the impact of untreated FCS on patient quality of life and long-term health risks.
Nature Reviews Cardiology, Published online: 24 September 2024; doi:10.1038/s41569-024-01083-1 John C. Lin and colleagues explore the history of racial disparities in cardiovascular outcomes and discuss the landmark findings of the CARDIA study and its contribution to the minority stress model.
Abstract Introduction Supraventricular tachycardia (SVT) is a common pediatric arrhythmia. Beta blockers (BBs) and calcium channel blockers (CCBs) are used for treatment despite little data examining their use. We describe the prescriptive tendencies, efficacy, and tolerability of BBs and CCBs used in the treatment of pediatric SVT. Methods and Results This is a multicenter retrospective cohort study from three academic children's hospitals.
Commentary based on Kloner RA, Burnett AL, Miner M, et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J Sex Med 2024;21:90-116.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content